Advancing outcome measures for the new era of drug development in cystic fibrosis.
about
Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher.Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapyAbsorptive clearance of DTPA as an aerosol-based biomarker in the cystic fibrosis airway.Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial.Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state.Plasma TGF-β₁ in pediatric cystic fibrosis: potential biomarker of lung disease and response to therapy.Cholesteryl esters are elevated in the lipid fraction of bronchoalveolar lavage fluid collected from pediatric cystic fibrosis patients.Potential of anti-inflammatory treatment for cystic fibrosis lung disease.Effect of treatment of cystic fibrosis pulmonary exacerbations on systemic inflammation.Outcome measures for clinical trials assessing treatment of cystic fibrosis lung disease.Gene modifiers in cystic fibrosis.Outcome measures for development of new therapies in cystic fibrosis: are we making progress and what are the next steps?Sputum biomarkers of inflammation in cystic fibrosis lung diseasePotential role of high-mobility group box 1 in cystic fibrosis airway disease.Progress in cystic fibrosis and the CF Therapeutics Development NetworkSputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis.Endophenotypes of obsessive-compulsive disorder: rationale, evidence and future potential.Inspissated oral secretions and a review of their clinical, biological, and physiological significance.Efficacy response in CF patients treated with ivacaftor: post-hoc analysis.Using hyperpolarized 3He MRI to evaluate treatment efficacy in cystic fibrosis patients.Sweat Chloride: The Critical Biomarker for Cystic Fibrosis Trials.
P2860
Q30238814-7739F039-E08B-4C3B-847E-CA54AAFD1838Q33697276-5B78F577-104F-45F1-9757-A5921F52EA77Q33840919-CE2EB529-FF24-4F8F-ADAA-BE74973EED43Q34118967-AEEA465F-B5E6-48BE-8295-5F487E8E820EQ34275485-C243181E-B7C0-4A61-A1F6-6509F7D9382CQ34342709-A56D503E-BB38-49BE-9FAF-ACC289A73817Q35046565-6E9424C0-578E-464D-AA44-4A15860F26A7Q35546970-52CB1FD4-201F-4AFC-8A8F-6A4EEC041B8CQ35557381-179F65A4-566C-4FE9-A83F-A80ACB8E063EQ35565168-285BE76A-7D12-47B6-A66D-62321F873BFEQ35801062-4EACAD90-6901-42B5-A951-C740FD103BB4Q36470683-6CAFA3CC-F93D-416B-BB69-804FF07D4F1DQ36891526-3D68BE62-0ACB-4B26-B910-E4188EE39DDFQ36891552-032E29A4-921C-4F54-8A9D-2B8D32AB1FC9Q36935244-B75C4D12-3AD2-4948-AE77-4AC9F66461F4Q37209004-02913F90-3FEE-4133-9AC5-4AAA020CAE47Q37463875-954C25F3-B571-49B7-B2A2-18D4E5165788Q37578478-AE35077E-8283-43F3-843C-EF7539AB9BDCQ38010515-E739E943-E795-47F0-BEF3-AAF99A50915BQ41259021-B39759C4-7A22-400F-9108-275564ADA485Q46555295-CFF7163B-558A-41A7-8F5B-27ED96BAD7A1Q48186189-0E8698EA-878D-40D9-96E9-D1E3189BB7A5
P2860
Advancing outcome measures for the new era of drug development in cystic fibrosis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Advancing outcome measures for the new era of drug development in cystic fibrosis.
@en
type
label
Advancing outcome measures for the new era of drug development in cystic fibrosis.
@en
prefLabel
Advancing outcome measures for the new era of drug development in cystic fibrosis.
@en
P2093
P2860
P1476
Advancing outcome measures for the new era of drug development in cystic fibrosis.
@en
P2093
Bonnie W Ramsey
Nicole Mayer-Hamblett
Richard A Kronmal
P2860
P304
P356
10.1513/PATS.200703-040BR
P577
2007-08-01T00:00:00Z